Hongkong Land Holdings Limited (HKHGF)
OTCMKTS · Delayed Price · Currency is USD
6.30
+0.02 (0.40%)
At close: Aug 4, 2025
Verve Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,781 | 2,002 | 1,844 | 2,244 | 2,384 | 2,094 | Upgrade | |
Revenue Growth (YoY) | -17.03% | 8.56% | -17.83% | -5.87% | 13.85% | -9.72% | Upgrade |
Cost of Revenue | 804.4 | 1,119 | 884.1 | 1,224 | 1,284 | 982.6 | Upgrade |
Gross Profit | 976.5 | 883.6 | 960.2 | 1,021 | 1,100 | 1,112 | Upgrade |
Selling, General & Admin | 212.2 | 209 | 221.6 | 214 | 208.5 | 190 | Upgrade |
Other Operating Expenses | -61.3 | -70 | -54.3 | -40.8 | -16 | -31.2 | Upgrade |
Operating Expenses | 150.9 | 139 | 167.3 | 173.2 | 192.5 | 158.8 | Upgrade |
Operating Income | 825.6 | 744.6 | 792.9 | 847.5 | 907.9 | 952.8 | Upgrade |
Interest Expense | -213.2 | -226 | -243.3 | -216 | -202.5 | -182.5 | Upgrade |
Interest & Investment Income | 66.4 | 78.8 | 81.5 | 66.8 | 67 | 79 | Upgrade |
Earnings From Equity Investments | 408.8 | 254.2 | 252.7 | 229.3 | 355.9 | 267.5 | Upgrade |
Currency Exchange Gain (Loss) | -7.6 | -7.6 | - | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -19 | -19 | -22.6 | -18.9 | -19.7 | -12.4 | Upgrade |
EBT Excluding Unusual Items | 1,061 | 825 | 861.2 | 908.7 | 1,109 | 1,104 | Upgrade |
Gain (Loss) on Sale of Assets | -19.2 | -14.2 | 15.9 | -2.8 | 37.6 | 7.2 | Upgrade |
Asset Writedown | -1,236 | -2,035 | -1,353 | -583.8 | -1,294 | -3,619 | Upgrade |
Other Unusual Items | - | - | 31.6 | 1.3 | - | - | Upgrade |
Pretax Income | -194 | -1,224 | -444.3 | 323.4 | -148.2 | -2,507 | Upgrade |
Income Tax Expense | 131.9 | 152.1 | 132.8 | 123.8 | 195.6 | 144.6 | Upgrade |
Earnings From Continuing Operations | -325.9 | -1,376 | -577.1 | 199.6 | -343.8 | -2,652 | Upgrade |
Minority Interest in Earnings | -5.1 | -9.1 | -5.2 | 3.1 | -5.4 | 4.4 | Upgrade |
Net Income | -331 | -1,385 | -582.3 | 202.7 | -349.2 | -2,647 | Upgrade |
Net Income to Common | -331 | -1,385 | -582.3 | 202.7 | -349.2 | -2,647 | Upgrade |
Shares Outstanding (Basic) | 2,204 | 2,207 | 2,215 | 2,254 | 2,328 | 2,334 | Upgrade |
Shares Outstanding (Diluted) | 2,204 | 2,207 | 2,215 | 2,254 | 2,328 | 2,334 | Upgrade |
Shares Change (YoY) | -0.21% | -0.38% | -1.71% | -3.20% | -0.24% | - | Upgrade |
EPS (Basic) | -0.15 | -0.63 | -0.26 | 0.09 | -0.15 | -1.13 | Upgrade |
EPS (Diluted) | -0.15 | -0.63 | -0.26 | 0.09 | -0.15 | -1.13 | Upgrade |
Free Cash Flow | 516.3 | 592.1 | 616.3 | 763.7 | 429.7 | 852 | Upgrade |
Free Cash Flow Per Share | 0.23 | 0.27 | 0.28 | 0.34 | 0.18 | 0.36 | Upgrade |
Dividend Per Share | 0.230 | 0.230 | 0.220 | 0.220 | 0.220 | 0.220 | Upgrade |
Dividend Growth | 4.54% | 4.54% | - | - | - | - | Upgrade |
Gross Margin | 54.83% | 44.13% | 52.06% | 45.48% | 46.15% | 53.08% | Upgrade |
Operating Margin | 46.36% | 37.19% | 42.99% | 37.76% | 38.08% | 45.50% | Upgrade |
Profit Margin | -18.59% | -69.17% | -31.57% | 9.03% | -14.65% | -126.42% | Upgrade |
Free Cash Flow Margin | 28.99% | 29.57% | 33.42% | 34.03% | 18.02% | 40.68% | Upgrade |
EBITDA | 836.6 | 754.7 | 806 | 860.6 | 920.5 | 963.6 | Upgrade |
EBITDA Margin | 46.98% | 37.70% | 43.70% | 38.34% | 38.61% | 46.01% | Upgrade |
D&A For EBITDA | 11 | 10.1 | 13.1 | 13.1 | 12.6 | 10.8 | Upgrade |
EBIT | 825.6 | 744.6 | 792.9 | 847.5 | 907.9 | 952.8 | Upgrade |
EBIT Margin | 46.36% | 37.19% | 42.99% | 37.76% | 38.08% | 45.50% | Upgrade |
Effective Tax Rate | - | - | - | 38.28% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.